FDA approves canagliflozin/metformin combination (Clinical Endocrinology News, 11 August 2014)
The Food and Drug Administration has approved Invokamet, a fixed-dose combination of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, and metformin, for type 2 diabetes. The drug will marketed in the USA by Janssen Pharmaceuticals.
Full article
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Food and Drug Administration (FDA) | Fortamet | Invokana | Metformin